These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 21145592)

  • 1. Aminopeptidase inhibition by the novel agent CHR-2797 (tosedostat) for the therapy of acute myeloid leukemia.
    Jenkins C; Hewamana S; Krige D; Pepper C; Burnett A
    Leuk Res; 2011 May; 35(5):677-81. PubMed ID: 21145592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I/II clinical study of Tosedostat, an inhibitor of aminopeptidases, in patients with acute myeloid leukemia and myelodysplasia.
    Löwenberg B; Morgan G; Ossenkoppele GJ; Burnett AK; Zachée P; Dührsen U; Dierickx D; Müller-Tidow C; Sonneveld P; Krug U; Bone E; Flores N; Richardson AF; Hooftman L; Jenkins C; Zweegman S; Davies F
    J Clin Oncol; 2010 Oct; 28(28):4333-8. PubMed ID: 20733120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CHR-2797: an antiproliferative aminopeptidase inhibitor that leads to amino acid deprivation in human leukemic cells.
    Krige D; Needham LA; Bawden LJ; Flores N; Farmer H; Miles LE; Stone E; Callaghan J; Chandler S; Clark VL; Kirwin-Jones P; Legris V; Owen J; Patel T; Wood S; Box G; Laber D; Odedra R; Wright A; Wood LM; Eccles SA; Bone EA; Ayscough A; Drummond AH
    Cancer Res; 2008 Aug; 68(16):6669-79. PubMed ID: 18701491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The HSP90 inhibitor NVP-AUY922-AG inhibits the PI3K and IKK signalling pathways and synergizes with cytarabine in acute myeloid leukaemia cells.
    Walsby EJ; Lazenby M; Pepper CJ; Knapper S; Burnett AK
    Br J Haematol; 2013 Apr; 161(1):57-67. PubMed ID: 23356405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tosedostat for the treatment of relapsed and refractory acute myeloid leukemia.
    DiNardo CD; Cortes JE
    Expert Opin Investig Drugs; 2014 Feb; 23(2):265-72. PubMed ID: 24313331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
    Lu C; Hassan HT
    Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomised evaluation of low-dose cytosine arabinoside (ara-C) plus tosedostat versus low-dose ara-C in older patients with acute myeloid leukaemia: results of the LI-1 trial.
    Dennis M; Burnett A; Hills R; Thomas I; Ariti C; Severinsen MT; Hemmaway C; Greaves P; Clark RE; Copland M; Russell N;
    Br J Haematol; 2021 Jul; 194(2):298-308. PubMed ID: 33961292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of tosedostat, a novel, oral agent for elderly patients with relapsed or refractory acute myeloid leukemia: a review of the Phase II OPAL trial.
    Mathisen MS; Ravandi F
    Future Oncol; 2012 Apr; 8(4):351-7. PubMed ID: 22515438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
    Walker AR; Komrokji RS; Ifthikharuddin J; Messina P; Mulford D; Becker M; Friedberg J; Oliva J; Phillips G; Liesveld JL; Abboud C
    Leuk Res; 2008 Dec; 32(12):1830-6. PubMed ID: 18571721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cyclin-dependent kinase inhibitor SNS-032 has single agent activity in AML cells and is highly synergistic with cytarabine.
    Walsby E; Lazenby M; Pepper C; Burnett AK
    Leukemia; 2011 Mar; 25(3):411-9. PubMed ID: 21212792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nuclear factor-kappaB as a potential therapeutic target for the novel cytotoxic agent LC-1 in acute myeloid leukaemia.
    Jenkins C; Hewamana S; Gilkes A; Neelakantan S; Crooks P; Mills K; Pepper C; Burnett A
    Br J Haematol; 2008 Dec; 143(5):661-71. PubMed ID: 19036014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
    Gandhi V; Estey E; Du M; Nowak B; Keating MJ; Plunkett W
    Clin Cancer Res; 1995 Feb; 1(2):169-78. PubMed ID: 9815970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heat shock protein 90 inhibition is cytotoxic to primary AML cells expressing mutant FLT3 and results in altered downstream signalling.
    Al Shaer L; Walsby E; Gilkes A; Tonks A; Walsh V; Mills K; Burnett A; Rowntree C
    Br J Haematol; 2008 May; 141(4):483-93. PubMed ID: 18373709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic induction of folate receptor beta by all-trans retinoic acid and histone deacetylase inhibitors in acute myelogenous leukemia cells: mechanism and utility in enhancing selective growth inhibition by antifolates.
    Qi H; Ratnam M
    Cancer Res; 2006 Jun; 66(11):5875-82. PubMed ID: 16740727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias.
    Karp JE; Passaniti A; Gojo I; Kaufmann S; Bible K; Garimella TS; Greer J; Briel J; Smith BD; Gore SD; Tidwell ML; Ross DD; Wright JJ; Colevas AD; Bauer KS
    Clin Cancer Res; 2005 Dec; 11(23):8403-12. PubMed ID: 16322302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Differentiation induction of myeloid leukemia cells by glucocorticoid--the differentiation induction effect in vitro and in vivo].
    Nakamaki T; Sakashita A; Sano M; Hino K; Suzuki K; Tomoyasu S; Tsuruoka N
    Rinsho Ketsueki; 1989 Feb; 30(2):149-57. PubMed ID: 2746870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current and emerging therapies for acute myeloid leukemia.
    Robak T; Wierzbowska A
    Clin Ther; 2009; 31 Pt 2():2349-70. PubMed ID: 20110045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype.
    Colado E; Alvarez-Fernández S; Maiso P; Martín-Sánchez J; Vidriales MB; Garayoa M; Ocio EM; Montero JC; Pandiella A; San Miguel JF
    Haematologica; 2008 Jan; 93(1):57-66. PubMed ID: 18166786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Enhanced sensitivity to cytosine arabinoside by combined stimulation of steel factor and GM-CSF in a factor-dependent leukemic cell line, MO7e--in terms of a possible clinical application to AML treatment].
    Gotoh A; Kawanishi Y; Kurosawa K; Miyazawa K; Ohtaka M; Aizawa S; Kimura Y; Yoshikawa O; Toyama K
    Rinsho Ketsueki; 1993 Jul; 34(7):821-8. PubMed ID: 7689660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Timed sequential therapy of acute leukemia with flavopiridol: in vitro model for a phase I clinical trial.
    Karp JE; Ross DD; Yang W; Tidwell ML; Wei Y; Greer J; Mann DL; Nakanishi T; Wright JJ; Colevas AD
    Clin Cancer Res; 2003 Jan; 9(1):307-15. PubMed ID: 12538483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.